Physician profile
Peter L Mohrer
NPI 1205800463
$38,053.60
in general payments reported to CMS, 2019-2025
16 companies · $7,646 in 2025
The $7,646 reported for 2025 was more than what 95% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $364 · 2020: $165 · 2021: $2,627 · 2022: $7,465 · 2023: $15K · 2024: $4,814 · 2025: $7,646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Food and Beverage: $2,481 · Consulting Fee: $360 · Education: $11.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,580.00 |
| Food and Beverage | $2,480.82 |
| Consulting Fee | $360.00 |
| Education | $11.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $32,703.77 | 2021-2025 | |
| Corium, LLC | $2,647.56 | 2022-2025 | Azstarys, Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $858.13 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $588.55 | 2020-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $284.58 | 2019-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $146.11 | 2019-2022 | |
| Allergan, INC. | $142.32 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $136.87 | 2025 | Fanapt |
| Neurocrine Biosciences, INC. | $125.00 | 2023 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $112.31 | 2025 | Cobenfy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $99.82 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.41 | 2019-2020 | |
| Alkermes, INC. | $48.60 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $45.51 | 2023 | Qelbree |
| Tms Neurohealth Centers INC. | $35.24 | 2025 | Tms Neurohealth Centers INC. |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $21.82 | 2024 | Abilify Asimtufii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Mohrer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.